Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July

BOSTON, May 08, 2017 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it has completed enrollment in its pivotal Phase 3 clinical study evaluating oral-only omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The Company expects to report top-line data from this study in mid-July. This study is designed to assess the efficacy and safety of once-daily oral-only omadacycline compared with twice-daily oral-only linezolid in subjects with ABSSSI.